Biomarkers /
EGFR
Back to Biomarkers List
Overview
EGFR (epidermal growth factor receptor, also known as ERBB1 and HER1) is a gene that encodes for the epidermal growth factor receptor protein. Missense mutations, deletions, and insertions are observed in cancers such as lung cancer and glioblastoma. Activating EGFR mutations increase the kinase activity of EGFR, leading to hyperactivation of downstream pro-survival signaling pathways (PMID: 15284455).
EGFR is altered in 6.82% of all cancers with non-small cell lung carcinoma, malignant glioma, breast carcinoma, colorectal adenocarcinoma, and melanoma having the greatest prevalence of alterations [3].
The most common alterations in EGFR are EGFR Mutation (7.26%), EGFR Mutation (germline) (7.26%), EGFR Mutation (somatic) (7.26%), EGFR Amplification (2.83%), and EGFR L858R (1.29%) [3].
Biomarker-Directed Therapies
EGFR is a predictive biomarker for use of afatinib, erlotinib, gefitinib, dacomitinib, osimertinib, crizotinib, and pembrolizumab in patients.
Non-small cell lung carcinoma has the most therapies with EGFR as a predictive biomarker.
Of the therapies with EGFR as a predictive biomarker, 6 are FDA-approved in at least one clinical setting and 6 have NCCN guidelines in at least one clinical setting.
EGFR Exon 19 Deletion, EGFR G719A, EGFR G719C, EGFR G719S, and EGFR L858R are the top alterations on EGFR targeted by therapies [4].
Afatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG, ASCO) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN, MCG) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE, SMC) |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN, MCG) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG, ASCO) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN, MCG) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE, BNF, SMC) |
Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG, ASCO) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN, MCG) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN, MCG) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE, SMC) |
Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG, ASCO) | |
| Note: Indicated for metastatic, EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) patients who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Preferred first-line therapy, per NCCN |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Preferred first-line therapy, per NCCN |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE, SMC) | |
| Note: Indicated for metastatic, EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) patients who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. |
Pembrolizumab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with an EGFR or ALK alteration: FDA-approved as second/subsequent line of therapy following targeted therapy. However, per NCCN, data in the second-line setting suggest that subsequent pembrolizumab monotherapy is less effective in tumors with an EGFR mutation or ALK rearrangement. |
Afatinib + Crizotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Clinical Trials
EGFR status serves as an inclusion eligibility criteria in 244 clinical trials, of which 199 are open and 45 are closed. Of the trials that contain EGFR status as an inclusion criterion, 5 are early phase 1 (2 open), 56 are phase 1 (41 open), 29 are phase 1/phase 2 (24 open), 111 are phase 2 (99 open), 5 are phase 2/phase 3 (4 open), 31 are phase 3 (26 open), 4 are phase 4 (2 open), and 3 are no phase specified (1 open).
Trials with EGFR status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, malignant solid tumor, glioblastoma, breast carcinoma, and lung adenocarcinoma [4].
The most frequent alterations to serve as inclusion eligibility criteria are EGFR Exon 19 Deletion, EGFR L858R, EGFR L861Q, EGFR Exon 19 Insertion, and EGFR S768I [4].
Osimertinib, erlotinib, gefitinib, afatinib, and pemetrexed are the most frequent therapies in trials with EGFR as an inclusion criteria [4].
Significance of EGFR in Diseases
Non-Small Cell Lung Carcinoma +
EGFR is mutated in 22.17% of non-small cell lung carcinoma patients [3].
EGFR is an inclusion criterion in 188 clinical trials for non-small cell lung carcinoma, of which 154 are open and 34 are closed. Of the trials that contain EGFR status and non-small cell lung carcinoma as inclusion criteria, 3 are early phase 1 (2 open), 39 are phase 1 (30 open), 25 are phase 1/phase 2 (20 open), 82 are phase 2 (73 open), 5 are phase 2/phase 3 (4 open), 27 are phase 3 (22 open), 4 are phase 4 (2 open), and 3 are no phase specified (1 open) [4].
Afatinib, erlotinib, gefitinib, osimertinib, dacomitinib, crizotinib, and pembrolizumab are currently approved for use in patients with EGFR mutation in non-small cell lung carcinoma [4].
Osimertinib, gefitinib, and erlotinib are the most frequent therapies in non-small cell lung carcinoma trials with EGFR alterations as inclusion criteria [4].
Malignant Solid Tumor +
EGFR is mutated in 6.38% of malignant solid tumor patients [3].
EGFR is an inclusion criterion in 27 clinical trials for malignant solid tumor, of which 21 are open and 6 are closed. Of the trials that contain EGFR status and malignant solid tumor as inclusion criteria, 9 are phase 1 (4 open), 6 are phase 1/phase 2 (5 open), and 12 are phase 2 (12 open) [4].
Palbociclib, olaparib, and vemurafenib are the most frequent therapies in malignant solid tumor trials with EGFR alterations as inclusion criteria [4].
Glioblastoma +
EGFR is mutated in 31.59% of glioblastoma patients [3].
EGFR is an inclusion criterion in 12 clinical trials for glioblastoma, of which 10 are open and 2 are closed. Of the trials that contain EGFR status and glioblastoma as inclusion criteria, 6 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].
Anti-egfr monoclonal antibody gc1118, afatinib, and atezolizumab are the most frequent therapies in glioblastoma trials with EGFR alterations as inclusion criteria [4].
Breast Carcinoma +
EGFR is mutated in 2.59% of breast carcinoma patients [3].
EGFR is an inclusion criterion in 9 clinical trials for breast carcinoma, of which 8 are open and 1 is closed. Of the trials that contain EGFR status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [4].
Trastuzumab, fulvestrant, and pi3k/mtor inhibitor ly3023414 are the most frequent therapies in breast carcinoma trials with EGFR alterations as inclusion criteria [4].
Lung Adenocarcinoma +
EGFR is mutated in 25.12% of lung adenocarcinoma patients [3].
EGFR is an inclusion criterion in 5 clinical trials for lung adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain EGFR status and lung adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open) [4].
Osimertinib is the most frequent therapy in lung adenocarcinoma trials with EGFR alterations as inclusion criteria [4].
Squamous Cell Lung Carcinoma +
EGFR is mutated in 7.09% of squamous cell lung carcinoma patients [3].
EGFR is an inclusion criterion in 4 clinical trials for squamous cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain EGFR status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Pi3k/mtor inhibitor ly3023414, vistusertib, and abemaciclib are the most frequent therapies in squamous cell lung carcinoma trials with EGFR alterations as inclusion criteria [4].
Glioma +
EGFR is mutated in 3.25% of glioma patients [3].
EGFR is an inclusion criterion in 4 clinical trials for glioma, of which 2 are open and 2 are closed. Of the trials that contain EGFR status and glioma as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (2 open), and 1 is phase 2 (0 open) [4].
Afatinib and lapatinib are the most frequent therapies in glioma trials with EGFR alterations as inclusion criteria [4].
Non-Hodgkin Lymphoma +
EGFR is mutated in 1.8% of non-hodgkin lymphoma patients [3].
EGFR is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain EGFR status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].
Pi3k/mtor inhibitor ly3023414, olaparib, and palbociclib are the most frequent therapies in non-hodgkin lymphoma trials with EGFR alterations as inclusion criteria [4].
Colorectal Carcinoma +
EGFR is mutated in 1.6% of colorectal carcinoma patients [3].
EGFR is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain EGFR status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Vistusertib, alectinib, and atezolizumab are the most frequent therapies in colorectal carcinoma trials with EGFR alterations as inclusion criteria [4].
Adenocarcinoma Of The Gastroesophageal Junction +
EGFR is mutated in 6.11% of adenocarcinoma of the gastroesophageal junction patients [3].
EGFR is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain EGFR status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 3 are phase 2 (3 open) [4].
Alectinib, atezolizumab, and cobimetinib are the most frequent therapies in adenocarcinoma of the gastroesophageal junction trials with EGFR alterations as inclusion criteria [4].
Gastric Carcinoma +
EGFR is mutated in 5.94% of gastric carcinoma patients [3].
EGFR is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR status and gastric carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].
Alectinib, atezolizumab, and cobimetinib are the most frequent therapies in gastric carcinoma trials with EGFR alterations as inclusion criteria [4].
Endometrial Carcinoma +
EGFR is mutated in 3.56% of endometrial carcinoma patients [3].
EGFR is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR status and endometrial carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Pi3k/mtor inhibitor ly3023414, vistusertib, and abemaciclib are the most frequent therapies in endometrial carcinoma trials with EGFR alterations as inclusion criteria [4].
Multiple Myeloma +
EGFR is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain EGFR status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [4].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with EGFR alterations as inclusion criteria [4].
Head And Neck Squamous Cell Carcinoma +
EGFR is mutated in 6.0% of head and neck squamous cell carcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].
Abemaciclib, alpelisib, and durvalumab are the most frequent therapies in head and neck squamous cell carcinoma trials with EGFR alterations as inclusion criteria [4].
Urothelial Carcinoma +
EGFR is mutated in 4.5% of urothelial carcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Afatinib is the most frequent therapy in urothelial carcinoma trials with EGFR alterations as inclusion criteria [4].
Lymphoma +
EGFR is mutated in 2.08% of lymphoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Sunitinib, palbociclib, and dasatinib are the most frequent therapies in lymphoma trials with EGFR alterations as inclusion criteria [4].
Pancreatic Carcinoma +
EGFR is mutated in 0.95% of pancreatic carcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in pancreatic carcinoma trials with EGFR alterations as inclusion criteria [4].
Cancer +
EGFR is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 1 is phase 1 (1 open) [4].
Pi3k/mtor inhibitor ly3023414, abemaciclib, and cisplatin are the most frequent therapies in cancer trials with EGFR alterations as inclusion criteria [4].
Malignant Glioma +
EGFR is mutated in 26.75% of malignant glioma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Egfr inhibitor abt-414, radiation therapy, and temozolomide are the most frequent therapies in malignant glioma trials with EGFR alterations as inclusion criteria [4].
Anaplastic Astrocytoma +
EGFR is mutated in 19.27% of anaplastic astrocytoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Afatinib is the most frequent therapy in anaplastic astrocytoma trials with EGFR alterations as inclusion criteria [4].
Small Cell Lung Carcinoma +
EGFR is mutated in 7.65% of small cell lung carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in small cell lung carcinoma trials with EGFR alterations as inclusion criteria [4].
Melanoma +
EGFR is mutated in 6.14% of melanoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in melanoma trials with EGFR alterations as inclusion criteria [4].
Gliosarcoma +
EGFR is mutated in 8.11% of gliosarcoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Lapatinib is the most frequent therapy in gliosarcoma trials with EGFR alterations as inclusion criteria [4].
Anaplastic Oligodendroglioma +
EGFR is mutated in 4.92% of anaplastic oligodendroglioma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Afatinib is the most frequent therapy in anaplastic oligodendroglioma trials with EGFR alterations as inclusion criteria [4].
Nasal Cavity And Paranasal Sinus Carcinoma +
EGFR is mutated in 4.44% of nasal cavity and paranasal sinus carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Anaplastic Oligoastrocytoma +
EGFR is mutated in 6.52% of anaplastic oligoastrocytoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for anaplastic oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Afatinib is the most frequent therapy in anaplastic oligoastrocytoma trials with EGFR alterations as inclusion criteria [4].
Gastric Adenocarcinoma +
EGFR is mutated in 6.25% of gastric adenocarcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Malignant Brain Neoplasm +
EGFR is mutated in 3.12% of malignant brain neoplasm patients [3].
EGFR is an inclusion criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Afatinib is the most frequent therapy in malignant brain neoplasm trials with EGFR alterations as inclusion criteria [4].
B-Cell Non-Hodgkin Lymphoma +
EGFR is mutated in 2.67% of B-cell non-hodgkin lymphoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with EGFR alterations as inclusion criteria [4].
Colorectal Adenocarcinoma +
EGFR is mutated in 3.29% of colorectal adenocarcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Nasopharyngeal Carcinoma +
EGFR is mutated in 1.69% of nasopharyngeal carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Hepatocellular Carcinoma +
EGFR is mutated in 2.2% of hepatocellular carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thymic Carcinoma +
EGFR is mutated in 1.33% of thymic carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in thymic carcinoma trials with EGFR alterations as inclusion criteria [4].
Renal Cell Carcinoma +
EGFR is mutated in 1.32% of renal cell carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in renal cell carcinoma trials with EGFR alterations as inclusion criteria [4].
Cholangiocarcinoma +
EGFR is mutated in 2.02% of cholangiocarcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Vistusertib, adavosertib, and capivasertib are the most frequent therapies in cholangiocarcinoma trials with EGFR alterations as inclusion criteria [4].
Thyroid Gland Carcinoma +
EGFR is mutated in 1.01% of thyroid gland carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in thyroid gland carcinoma trials with EGFR alterations as inclusion criteria [4].
Meningioma +
EGFR is mutated in 0.89% of meningioma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and meningioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Afatinib is the most frequent therapy in meningioma trials with EGFR alterations as inclusion criteria [4].
Prostate Carcinoma +
EGFR is mutated in 1.19% of prostate carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].
Everolimus and placebo are the most frequent therapies in prostate carcinoma trials with EGFR alterations as inclusion criteria [4].
Gastrointestinal Stromal Tumor +
EGFR is mutated in 0.85% of gastrointestinal stromal tumor patients [3].
EGFR is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Brain Metastasis +
EGFR is an inclusion criterion in 1 clinical trial for brain metastasis, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and brain metastasis as inclusion criteria, 1 is phase 1 (1 open) [4].
Afatinib is the most frequent therapy in brain metastasis trials with EGFR alterations as inclusion criteria [4].
Chordoma +
EGFR is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and chordoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Afatinib is the most frequent therapy in chordoma trials with EGFR alterations as inclusion criteria [4].
Hepatobiliary Neoplasm +
EGFR is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Histiocytic And Dendritic Cell Neoplasm +
EGFR is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Pi3k/mtor inhibitor ly3023414 is the most frequent therapy in histiocytic and dendritic cell neoplasm trials with EGFR alterations as inclusion criteria [4].
Lip And Oral Cavity Carcinoma +
EGFR is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Laryngeal Neoplasm +
EGFR is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Leptomeningeal Neoplasm +
EGFR is an inclusion criterion in 1 clinical trial for malignant leptomeningeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant leptomeningeal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Afatinib is the most frequent therapy in malignant leptomeningeal neoplasm trials with EGFR alterations as inclusion criteria [4].
Malignant Salivary Gland Neoplasm +
EGFR is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Medulloblastoma +
EGFR is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Afatinib is the most frequent therapy in medulloblastoma trials with EGFR alterations as inclusion criteria [4].
Oropharyngeal Carcinoma +
EGFR is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ovarian Carcinoma +
EGFR is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in ovarian carcinoma trials with EGFR alterations as inclusion criteria [4].
Pancreatic Ductal Adenocarcinoma +
EGFR is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Peritoneal Mesothelioma +
EGFR is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pi3k/mtor inhibitor ly3023414, abemaciclib, and cisplatin are the most frequent therapies in peritoneal mesothelioma trials with EGFR alterations as inclusion criteria [4].
Pituitary Gland Neoplasm +
EGFR is an inclusion criterion in 1 clinical trial for pituitary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and pituitary gland neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Afatinib is the most frequent therapy in pituitary gland neoplasm trials with EGFR alterations as inclusion criteria [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
